Dendreon (DNDN) fell a heartbreaking 62% in AH trading after its earnings report  showed weak...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN) fell a heartbreaking 62% in AH trading after its earnings report  showed weak sales of cancer drug Provenge, prompting the firm to abandon its sales guidance and cut jobs. Annual sales of Provenge, Dendreon's only marketed product, will likely be closer to $200M than the $350M-400M previously projected.